Question

It is generally agreed that a certain standard treatment yields a mean survival period of 4.2...

It is generally agreed that a certain standard treatment yields a mean survival period of 4.2 years for cancer patient. A new treatment is administered to 60 patients and their duration of survival is recorded. The sample mean and standard deviation of the duration is 4.5 years and 0.8 years, respectively. Does the new treatment increase the mean survival period? Choose the appropriate hypotheses to test the claim.

Homework Answers

Answer #1

Here, we have to use one sample t test for the population mean.

The null and alternative hypotheses are given as below:

H0: µ = 4.2 versus Ha: µ > 4.2

This is an upper tailed test.

The test statistic formula is given as below:

t = (Xbar - µ)/[S/sqrt(n)]

From given data, we have

µ = 4.2

Xbar = 4.5

S = 0.8

n = 60

df = n – 1 = 59

α = 0.05

Critical value = 1.6711

(by using t-table or excel)

t = (Xbar - µ)/[S/sqrt(n)]

t = (4.5 - 4.2)/[0.8/sqrt(60)]

t = 2.9047

P-value = 0.0026

(by using t-table)

P-value < α = 0.05

So, we reject the null hypothesis

There is sufficient evidence to conclude that the new treatment increase the mean survival period.

Know the answer?
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for?
Ask your own homework help question
Similar Questions
It is claimed that a new treatment is more effective than the standard treatment for prolonging...
It is claimed that a new treatment is more effective than the standard treatment for prolonging the lives of terminal cancer patients. The standard treatment has been in use for a long time, and from records in medical journals, the mean survival period is known to be 4.2 years. The new treatment is administered to 80 patients and their duration of survival recorded. The sample mean and the standard deviation are found to be 4.5 and 1.1 years, respectively. Answer...
It is claimed that a new treatment for prolonging the lives of cancer patients is more...
It is claimed that a new treatment for prolonging the lives of cancer patients is more effective than the standard one. Records of earlier research show the mean survival period to have been 4.3 years with the standard treatment. The new teatment is administered to a sample of 20 patients, and the durations of their survival are recorded. The sample mean is 4.6 years, and the standard deviation is 1.2 years. Is the claimed effectiveness of the new method supported...
The mean survival time for patients with a particular form of disease is 4 years. A...
The mean survival time for patients with a particular form of disease is 4 years. A new treatment is tried on 20 patients with this particular disease and their average survival time is 4.7 years with a standard deviation of 1.5 years. (a) State the direction of the alternative hypothesis to test if the new treatment constitutes a significant improvement in survival time. Type gt (greater than), ge (greater than or equal to), lt (less than), le (less than or...
A researcher is creating a new treatment protocol for Myelodysplastic Syndrome (MDS), a form of preleukemia....
A researcher is creating a new treatment protocol for Myelodysplastic Syndrome (MDS), a form of preleukemia. Following the old treatment protocol, 32% of patients with MDS will develop leukemia within 5 years of MDS diagnosis. He believes his new treatment protocol will lead to fewer MDS patients developing leukemia. He takes a random sample of 100 individuals on his new treatment protocol. Of these 100 individuals, 27 develop leukemia within 5 years of MDS diagnosis. Create a 99% confidence interval...
After listening to this podcast, list and discuss the safe injection practices you should follow to...
After listening to this podcast, list and discuss the safe injection practices you should follow to prevent causing harm. Protecting Patients from Unsafe Injections: What Every Provider Needs to Know [Announcer] This program is presented by the Centers for Disease Control and Prevention. [Joyanna Wendt] Hello. I’m Dr. Joyanna Wendt, a Medical Officer at the Centers for Disease Control and Prevention, or CDC, and today we’re talking about injection safety. I know some of you are thinking, “That’s so basic....